Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder

Core Viewpoint - Clearmind Medicine Inc. has achieved a significant milestone by dosing the first participant with its proprietary drug candidate CMND-100 in a Phase I/IIa clinical trial aimed at treating Alcohol Use Disorder (AUD) [1][3]. Group 1: Clinical Trial Details - The Phase I/IIa trial is being conducted at prestigious clinical sites, including Yale School of Medicine, Johns Hopkins University, and medical centers in Israel [2]. - The trial's objectives include evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, as well as assessing its preliminary efficacy in reducing alcohol cravings and consumption [2][3]. - This trial represents the first time Clearmind's neuroplastogen compound has been administered to humans in a controlled clinical setting [3]. Group 2: Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address significant health issues, particularly AUD [4]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].